Left-side portal hypertension(LSPH)is a rare cause of intraabdominal venous hypertension.In most of cases,LSPH is due to pancreatic diseases,especially chronic pancreatitis,but it is also described in other abdominal ...Left-side portal hypertension(LSPH)is a rare cause of intraabdominal venous hypertension.In most of cases,LSPH is due to pancreatic diseases,especially chronic pancreatitis,but it is also described in other abdominal diseases(i.e.,retroperitoneal fibrosis or perineal abscess)after abdominal surgery(i.e.,pancreatic surgery,liver transplantation)or endovascular procedures[1–4].展开更多
Hepatitis C virus(HCV)infection is a major cause of liver disease and hepatocellular carcinoma worldwide(1).HCV is a blood-borne infection and prevalence is particularly high in patients with a history of injective dr...Hepatitis C virus(HCV)infection is a major cause of liver disease and hepatocellular carcinoma worldwide(1).HCV is a blood-borne infection and prevalence is particularly high in patients with a history of injective drug use or unsafe health care or sexual practices.Substance use disorder(SUD),and especially opioid misuse is a growing problem worldwide(2).This is particularly relevant in the United States(US)where opioid misuse has raised sharply in the last years(3,4),termed also opioid epidemic.SUD is associated with an increase incidence of HCV infections and reinfections and associated liver disease(2,4).Moreover,alcohol use disorder is frequent in patients with SUD(5),representing another major risk factor for chronic liver disease in this population.Patients with SUD often experience poor access to health care resulting in higher mortality(5,6).Finally,SUD is associated with psychiatric conditions and social problems such as housing instability,unemployment,and reduced access to medical care(7)which could result in a reduced access and compliance to HCV treatment.展开更多
文摘Left-side portal hypertension(LSPH)is a rare cause of intraabdominal venous hypertension.In most of cases,LSPH is due to pancreatic diseases,especially chronic pancreatitis,but it is also described in other abdominal diseases(i.e.,retroperitoneal fibrosis or perineal abscess)after abdominal surgery(i.e.,pancreatic surgery,liver transplantation)or endovascular procedures[1–4].
基金supported by ARC,Paris and Institut Hospitalo-Universitaire,Strasbourg(TheraHCC1.0and 2.0 IHUARC IHU201301187 and IHUARC2019 to TFB)the European Union(ERC-AdG-2014-671231-HEPCIR to TFB,EU H2020-667273-HEPCAR to TFB,and INTERREG-IV-Rhin Supérieur-FEDER-Hepato-Regio-Net 2012 to TFB)+5 种基金ANRS,Paris(2013/108 and ECTZ103701 to TFB)NIH(CA233794,CA209940,R21CA209940,and R03AI131066 to TFB)US Department of Defense(W81XWH-16-1-0363 to TFB)the Foundation of the University of Strasbourg(HEPKIN to TFB)and the Institut Universitaire de France(IUF,TFB)the framework of the LABEX ANR-10-LABX-0028_HEPSYSInserm Plan Cancer and benefits from funding from the state managed by the French National Research Agency as part of the Investments for the future program.
文摘Hepatitis C virus(HCV)infection is a major cause of liver disease and hepatocellular carcinoma worldwide(1).HCV is a blood-borne infection and prevalence is particularly high in patients with a history of injective drug use or unsafe health care or sexual practices.Substance use disorder(SUD),and especially opioid misuse is a growing problem worldwide(2).This is particularly relevant in the United States(US)where opioid misuse has raised sharply in the last years(3,4),termed also opioid epidemic.SUD is associated with an increase incidence of HCV infections and reinfections and associated liver disease(2,4).Moreover,alcohol use disorder is frequent in patients with SUD(5),representing another major risk factor for chronic liver disease in this population.Patients with SUD often experience poor access to health care resulting in higher mortality(5,6).Finally,SUD is associated with psychiatric conditions and social problems such as housing instability,unemployment,and reduced access to medical care(7)which could result in a reduced access and compliance to HCV treatment.
